The Evolution of AI in Clinical Settings: ChatGPT Training

By Sumona Bose

March 12, 2024

Introduction

ChatGPT (Generative Pre-trained Transformer) stands as a prominent Artificial Intelligence (AI) language model rooted in the transformer architecture. This neural network excels in processing sequential data, particularly text, through extensive exposure to vast text datasets. The training process involves pattern recognition and relationship establishment within the data, culminating in the generation of coherent language. Fine-tuning, complemented by human input and reinforcement learning from human feedback (RLHP), refines ChatGPT’s responses to various queries. ChatGPT’s most recent development is its GPT-4, the large language model (LLM) has been updated to understand, interpret and analyse images. These kind of developments indicate the evolution of AI in clinical settings.

The potential of GPT-4 in Medical Image Analysis

The potential impact on medical diagnostics remains significant. By leveraging image analysis, GPT-4 could enhance medical professionals’ diagnostic accuracy and speed, particularly in underserved regions. Evaluating GPT-4’s diagnostic prowess involved exposing it to diverse medical imaging modalities, from X-rays to Magnetic Resonance Imaging (MRI) and Optical coherence tomography (OCT) images. As demonstrated in Figure 1, GPT-4 can respond to prompts which specifically direct queries on interpreting medical images such as MRIs and OCTs.

Enhancing GPT-4’s image analysis proficiency necessitates further training on extensive medical image datasets to grasp nuanced patterns and correlations crucial for accurate diagnoses. While GPT-4 boasts a myriad of capabilities, it also harbours limitations, notably its reliance on training data patterns. This reliance implies potential performance disparities when faced with novel challenges or data misaligned with its training corpus. Addressing AI biases demands the incorporation of diverse datasets to fortify the model’s adaptability and mitigate predispositions in decision-making processes.

Figure 1: GPT-4 responses to two prompts with different links of the same image

Challenges and Considerations in GPT-4 Utilisation

GPT-4’s potential limitations include contextual understanding gaps, leading to potential misconceptions and inaccuracies, especially in technical domains. Users must verify information independently due to potential unreliability. The opaque nature of AI models demands cautious interpretation of outputs to avoid errors. In dynamic fields like healthcare, outdated or erroneous responses may occur. Furthermore, privacy concerns arise from potential data collection practices. Competing LLMs like Google’s Gemini (formerly Bard) and Meta’s LlaMa 2 with image analysis capabilities signal a growing landscape.Future efforts should focus on equitable and accountable LLM development through open-source codes and oversight mechanisms.

Conclusion

While GPT-4 showcases remarkable advancements in automated medical image analysis, challenges such as contextual understanding, reliability, and privacy concerns persist. As the field evolves with new models like Gemini and LlaMa 2, prioritising accountability and equity through open-source practices is crucial for the future of AI-driven healthcare innovations. Would you use GPT-4 to interpret your medical images?

Reference url

Recent Posts

drug pricing analysis
            

Drug Pricing Analysis: ICER’s Launch Price and Access Report Aims to Enhance Affordability in Pharma

💡 Are we paying too much for the medicines we need?

The Institute for Clinical and Economic Review (ICER) has released the protocol for its first annual “Launch Price and Access Report,” shedding light on the alarming rise of drug prices in the U.S. and the barriers patients face in accessing treatments. This comprehensive analysis not only explores price trends but also highlights the disconnect between drug pricing and its clinical value.

Dive into key findings that could shape the future of drug policy, affordability, and patient access.

Read the full article to discover more!

#SyenzaNews #HealthEconomics #MarketAccess

anticancer drug pricing
        

Trends in Anticancer Drug Pricing: Analyzing Medicare Launch Prices and Impact of the IRA

💸 Rising anticancer drug prices are putting Medicare’s sustainability at risk.

A recent study published in JAMA sheds light on the alarming trends in anticancer drug pricing under Medicare Part D, revealing that mean monthly costs have surged from approximately $11,000 to nearly $28,000 between 2012 and 2025. Despite the Inflation Reduction Act’s efforts, the data indicates that this upward trajectory shows no signs of abating.

Explore the study’s key insights and what they mean for the future of patient access and healthcare policy.

#SyenzaNews #pharmaceuticals #healthcarepolicy

AIM-NASH AI tool
   

EMA AI Tool Qualification: How the AIM-NASH Approval Sets a Roadmap for Medical AI

🚨 EMA Qualifies First AI Tool for Drug Development 🚨

The recent approval of AIM-NASH marks a turning point for AI in clinical research.

But this is more than a milestone—it’s a roadmap.

In our latest overview, we unpack six key lessons from the EMA qualification that pharma and AI teams need to know—on validation, model locking, clinical utility, and more.

#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.